These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 7983499)

  • 41. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
    Perfect JR; Cox GM; Dodge RK; Schell WA
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1910-3. PubMed ID: 8843302
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
    Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
    Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
    Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
    Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro susceptibility of Trichosporon beigelii to antifungal agents.
    Perparim K; Nagai H; Hashimoto A; Goto Y; Tashiro T; Nasu M
    J Chemother; 1996 Dec; 8(6):445-8. PubMed ID: 8981185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans.
    Barchiesi F; Del Poeta M; Morbiducci V; Ancarani F; Scalise G
    Mycopathologia; 1993 Oct; 124(1):19-25. PubMed ID: 8159215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Turbidimetric and visual criteria for in vitro susceptibility testing of Cryptococcus neoformans clinical isolates.
    Del Poeta M; Barchiesi F; Arzeni D; Marinucci G; Scalise G
    Mycoses; 1994; 37(11-12):411-6. PubMed ID: 7659128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study.
    Anaissie EJ; Paetznick VL; Ensign LG; Espinel-Ingroff A; Galgiani JN; Hitchcock CA; LaRocco M; Patterson T; Pfaller MA; Rex JH; Rinaldi MG
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2387-91. PubMed ID: 8891149
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Susceptibility of clinical isolates of Fusarium to antifungal drugs.
    Speeleveld E; Gordts B; Van Landuyt HW; De Vroey C; Raes-Wuytack C
    Mycoses; 1996; 39(1-2):37-40. PubMed ID: 8786755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.
    Espinel-Ingroff A; Canton E; Gibbs D; Wang A
    J Clin Microbiol; 2007 Mar; 45(3):858-64. PubMed ID: 17215342
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The postantibiotic effect of antifungal agents against common pathogenic yeasts.
    Turnidge JD; Gudmundsson S; Vogelman B; Craig WA
    J Antimicrob Chemother; 1994 Jul; 34(1):83-92. PubMed ID: 7961219
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
    Dannaoui E; Abdul M; Arpin M; Michel-Nguyen A; Piens MA; Favel A; Lortholary O; Dromer F;
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2464-70. PubMed ID: 16801427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [In vitro antifungal susceptibility of dematiaceous filamentous fungi using the E-test].
    Vivas JR; Torres-Rodríguez JM
    Rev Esp Quimioter; 2001 Jun; 14(2):191-7. PubMed ID: 11704774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB; Sujatha S; Parija SC
    Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DNA fingerprinting pattern and susceptibility to antifungal drugs in Cryptococcus neoformans variety grubii isolates from Barcelona city and rural environmental samples.
    Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T; Baró-Tomás T; Alía-Aponte C; Lázera MS
    Mycopathologia; 2005 Aug; 160(1):9-14. PubMed ID: 16160762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine.
    Pfaller MA; Bale M; Buschelman B; Lancaster M; Espinel-Ingroff A; Rex JH; Rinaldi MG; Cooper CR; McGinnis MR
    J Clin Microbiol; 1995 May; 33(5):1104-7. PubMed ID: 7615713
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro susceptibility to antifungal agents of environmental Cryptococcus spp. isolated in the city of Ribeirão Preto, São Paulo, Brazil.
    Pedroso RS; Ferreira JC; Candido RC
    Mem Inst Oswaldo Cruz; 2006 May; 101(3):239-43. PubMed ID: 16862315
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.
    Nguyen MH; Barchiesi F; McGough DA; Yu VL; Rinaldi MG
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1691-5. PubMed ID: 7486902
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro susceptibility of Cryptococcus gattii clinical isolates.
    Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
    Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
    Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of pH and buffer system on the in-vitro activity of five antifungals against yeasts.
    Gadea I; Cuenca M; Gegúndez MI; Zapardiel J; Valero ML; Soriano F
    J Antimicrob Chemother; 1997 Apr; 39(4):453-9. PubMed ID: 9145817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.